Cell signaling pathways are integral to regulating key cellular functions, such as growth, survival, and migration. In cancer, these pathways are frequently altered, contributing to unchecked cell proliferation and the ability to evade cell death mechanisms. Critical signaling pathways, including the PI3K/Akt, MAPK/ERK, and Wnt/β-catenin pathways, are often hijacked in cancer cells, enabling them to bypass normal cellular controls. These disruptions not only promote tumor growth but also facilitate cancer's spread to other parts of the body. Targeting these signaling pathways with specific inhibitors is a promising therapeutic approach, aiming to restore normal cellular function and limit cancer cell survival and metastasis, thereby offering potential for more effective, targeted treatments.